Navigation Links
Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
Date:3/18/2009

disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes are described in greater detail in the reports Nile files with Securities and Exchange Commission, including the "Risk Factors" section in Item 1A of the Form 10-K Nile filed with the Securities and Exchange Commission on March 12, 2009. Nile is providing this information as of the date of this press release and does not undertake any obliga
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at the Needham Cancer Therapeutics Conference
2. Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
(Date:11/24/2014)... BELLINGHAM, Washington, USA (PRWEB) November 23, 2014 ... the dynamic field of optics and photonics is now available ... no or very low cost. SPIE, the international society ... making access to the complete SPIE Digital Library ... a subsidized price. , “Light-based technologies are integral to all ...
(Date:11/24/2014)... 24, 2014  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... Ltd.,  Case No. 3:13-cv-03494-M and  Spherix v. Uniden ... in the United States District Court for the ... On November 21, 2014 the ...
(Date:11/22/2014)... 21, 2014 During his lifetime Richard ... need to surround himself with great people and take ... his friends often marveled at his extraordinarily courageous attitude ... life and -- even with his death impending—that’s how ... disease that would ultimately take his life. , Carrying ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... Neurognostics, Inc ., a Wisconsin company specializing ... announced today that the Food and Drug Administration (FDA) ... its trademarked MindState fDAD. MindState fDAD had previously ... acquisition device. The Special 510(k) allows Neurognostics to enhance ...
... Merge eMed , a Merge Healthcare ... company, today announced the release of Cedara I-ReadMammo ... mammography workstation software product is designed to help ... in adopting digital mammography. , ,I-ReadMammo was ...
... happen. In a country that invented take out food, that is ... is perpetually in motion, it was inevitable that work and indeed ... ten years, the place where knowledge work happens has shifted from ... deck, in a subway car, walking down the street or of ...
Cached Biology Technology:Who moved the workplace? 2Who moved the workplace? 3Who moved the workplace? 4
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
(Date:11/4/2014)... examining only marketing directed at children on the ... found that the majority of black, middle-income and ... tactics. , Authored by Arizona State University researcher ... the first to examine the use of child-directed ... food restaurants and its relationship to demographics. It ...
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... technology that uses "green" chemistry to help microbes break ... has earned kudos from the editors of Environmental Protection ... the Year. , The technology, which was invented by ... and licensed and manufactured by EOS Remediation, LLC, a ...
... , This release is available in French ... has played a role in the development of the many ... dart frog, according to a study that will be published ... University of Montreal biologist Mathieu Chouteau. The researcher,s methodology was ...
... James Wilkinson at the University of Southampton,s Optoelectronics ... Council (ERC) Advanced Grant to realise tools for ... analysis in water pollution and food safety. , ... biophotonics research in near- to mid-infra-red devices. ...
Cached Biology News:Predators drive the evolution of poison dart frogs' skin patterns 2
More cell-permeant than acridine orange....
Anti-rat Ig HRP detection kit...
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
Used in May-Grunwald Giemsa stain....
Biology Products: